Ligustilide inhibits the activation of cancer-associated fibroblasts.
CAF
Inhibit
Ligustilide
TLR4
α-SMA
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
03
12
2018
revised:
16
12
2018
accepted:
18
12
2018
pubmed:
24
12
2018
medline:
2
3
2019
entrez:
22
12
2018
Statut:
ppublish
Résumé
The purpose of this work was to study the effects and underlying molecular mechanisms of ligustilide on cancer-associated fibroblasts (CAFs). The effects of ligustilide on the growth of CAFs and splenocytes were detected by MTT assay, and flow cytometry was used to detect effects on T-cell proliferation. Western blotting was used to detect the expression levels of CAF-related proteins after ligustilide treatment. This study found that ligustilide had no effect on the growth of splenocytes but that it could change the immunosuppressive function of CAFs through the TLR4-NF-κB pathway and restore T-cell proliferation previously inhibited by the CAF supernatant. Thus, ligustilide is expected to be a candidate for new antitumor drugs.
Identifiants
pubmed: 30576705
pii: S0024-3205(18)30825-7
doi: 10.1016/j.lfs.2018.12.032
pii:
doi:
Substances chimiques
ligustilide
4431-01-0
4-Butyrolactone
OL659KIY4X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-64Informations de copyright
Copyright © 2018. Published by Elsevier Inc.